share_log

424B5: Prospectus

424B5: Prospectus

424B5:募资说明书
美股SEC公告 ·  01/06 20:03

Moomoo AI 已提取核心信息

Aclarion, Inc. has announced a direct offering of 3,380,276 shares of common stock at $0.142 per share, raising gross proceeds of approximately $480,000. The offering is expected to close on or about January 6, 2025.The company intends to use the net proceeds to fund market development, clinical evidence, product development, quality initiatives, and general administrative support. Dawson James Securities, Inc. is acting as the exclusive placement agent for the offering.Aclarion is currently not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements. The company has until April 7, 2025 to regain compliance with the bid price requirement and until January 31, 2025 for the stockholders' equity requirement. Aclarion is evaluating options to regain compliance and maintain its Nasdaq listing.
Aclarion, Inc. has announced a direct offering of 3,380,276 shares of common stock at $0.142 per share, raising gross proceeds of approximately $480,000. The offering is expected to close on or about January 6, 2025.The company intends to use the net proceeds to fund market development, clinical evidence, product development, quality initiatives, and general administrative support. Dawson James Securities, Inc. is acting as the exclusive placement agent for the offering.Aclarion is currently not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements. The company has until April 7, 2025 to regain compliance with the bid price requirement and until January 31, 2025 for the stockholders' equity requirement. Aclarion is evaluating options to regain compliance and maintain its Nasdaq listing.
Aclarion, Inc. 宣布以每股0.142美元直接发行3,380,276股普通股,预计将筹集约48万美元的总收益。此次发行预计将在2025年1月6日左右完成。公司打算利用净收益来资助市场开发、临床证据、产品开发、质量计划和一般行政支持。Dawson James Securities, Inc. 作为此次发行的独家配售代理。Aclarion目前不符合纳斯达克的最低买盘价格和股东权益要求。公司有直到2025年4月7日的时间来恢复符合买盘价格要求,并有直到2025年1月31日的时间来满足股东权益要求。Aclarion正在评估期权以恢复合规并维持其在纳斯达克的上市。
Aclarion, Inc. 宣布以每股0.142美元直接发行3,380,276股普通股,预计将筹集约48万美元的总收益。此次发行预计将在2025年1月6日左右完成。公司打算利用净收益来资助市场开发、临床证据、产品开发、质量计划和一般行政支持。Dawson James Securities, Inc. 作为此次发行的独家配售代理。Aclarion目前不符合纳斯达克的最低买盘价格和股东权益要求。公司有直到2025年4月7日的时间来恢复符合买盘价格要求,并有直到2025年1月31日的时间来满足股东权益要求。Aclarion正在评估期权以恢复合规并维持其在纳斯达克的上市。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息